首页> 外文期刊>Radiology and Oncology >Percutaneous transthoracic CT guided biopsies of lung lesions; fine needle aspiration biopsy versus core biopsy
【24h】

Percutaneous transthoracic CT guided biopsies of lung lesions; fine needle aspiration biopsy versus core biopsy

机译:经皮经胸CT引导下的肺部病变活检;细针穿刺活检与核心活检

获取原文
           

摘要

Background. The purpose of this retrospective study was to compare the results and complication rate in CT guided percutaneous trans-thoracic fine needle aspiration biopsies (FNAB) and core biopsies of lung lesions, and to determine the applicability of these needles.Patients and methods. In 242 patients (166 males; 76 females) with mean age of 58.9 years (13-84 years) CT guided biopsies of lung lesions were performed on dual slice CT equipment. The average diameter of lung lesion was 2.9 cm (1.2-6.3 cm). For FNAB's 20 - 22 G Chiba needles and for core biopsies 14 G biopsy needles were used. The samples were sent for the histological analysis. The cytological or histological results and the eventual complications were compared.Results. FNAB's cytological samples were adequate for definitive diagnosis in 117 patients (79.60 %) and inadequate in 30 patients (20.40 %). Core biopsies samples were adequate in 92 (96.85 %) patients and non-representative (necrotic tissue) in 3 (3.15 %). Pneumothorax as the most frequent complication was detected in 14 (9.7 %) of the patients in the group of FNAB's and in 30 (31.5 %) of the patients with the core biopsy group.Conclusions. The results showed that percutaneous transthoracic CT guided biopsies of lung lesions were an effective and safe procedure in the diagnosis of lung lesions. Core biopsy gives a higher percentage of representative samples than FNAB, and is a preferred method regardless of the higher rate of complications.
机译:背景。这项回顾性研究的目的是比较CT引导的经皮经胸穿刺细针穿刺活检(FNAB)和肺部病变的核心活检的结果和并发症发生率,并确定这些针的适用性,患者和方法。在双片CT设备上对平均年龄为58.9岁(13-84岁)的242例患者(男166例,女76例)进​​行了CT引导的肺部病变活检。肺部病变的平均直径为2.9厘米(1.2-6.3厘米)。对于FNAB的20-22 G千叶针和核心活检,使用14 G活检针。样品被送去进行组织学分析。比较细胞学或组织学结果以及最终并发症。 FNAB的细胞学样本足以进行117例患者的确诊(79.60%),而不足30例(20.40%)的确诊。 92例(96.85%)患者的核心活检样本足够,而3例(3.15%)的非代表性(坏死组织)样本足够。 FNAB组的患者中有14例(9.7%)和核心活检组的30例(31.5%)中发现了气胸为最常见的并发症。结果表明,经皮经胸CT引导下的肺部病变活检是诊断肺部病变的有效且安全的方法。核心活检比FNAB代表的样本百分比更高,并且是首选方法,而不管并发症的发生率更高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号